GeneLink, Inc. (GNLKQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GeneLink, Inc. (GNLKQ) with AI Score 49/100 (Weak). GeneLink, Inc. specializes in personalized health solutions, offering DNA assessment services, custom supplements, and skincare products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026GeneLink, Inc. (GNLKQ) Healthcare & Pipeline Overview
GeneLink, Inc., founded in 1994, provides personalized health solutions through DNA assessment services, custom supplements, and skincare products. Operating in the biotechnology sector, the company focuses on individualized wellness, but faces challenges with profitability and OTC market risks, reflected in its negative P/E ratio and significant beta.
Investment Thesis
Investing in GeneLink, Inc. (GNLKQ) presents a high-risk, high-reward scenario. The company's focus on personalized health solutions through DNA assessment services aligns with growing consumer interest in preventative and individualized healthcare. However, the company's negative P/E ratio and significant beta of -157.42 indicate substantial financial instability and volatility. Growth catalysts may include expanding its product line and strategic partnerships to broaden market reach. Key value drivers would be achieving profitability and demonstrating sustainable revenue growth. The OTC market listing introduces additional risks related to liquidity and regulatory oversight. Investors should carefully weigh the potential for growth in the personalized health market against the company's current financial challenges and the risks associated with OTC trading.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
- P/E Ratio of -0.00 reflects that the company is not currently profitable.
- Profit Margin of -142.9% demonstrates significant losses relative to revenue.
- Gross Margin of 21.8% suggests some ability to generate profit from sales before operating expenses.
- Beta of -157.42 indicates an inverse correlation to the market, but also suggests high volatility and potential instability.
Competitors & Peers
Strengths
- Personalized health solutions based on DNA assessment.
- Customized supplement formulations.
- Proprietary technology for DNA analysis.
- Direct-to-consumer sales model.
Weaknesses
- Negative profit margin and financial instability.
- Limited market capitalization.
- OTC market listing with associated risks.
- Dependence on a niche market.
Catalysts
- Upcoming: Potential partnerships with healthcare providers to expand distribution channels.
- Upcoming: Launch of new DNA assessment services targeting specific health concerns.
- Ongoing: Direct-to-consumer marketing efforts to increase brand awareness and drive sales.
Risks
- Potential: Increased competition from established players in the biotechnology sector.
- Potential: Regulatory changes affecting DNA assessment and supplement industries.
- Ongoing: Negative profit margin and financial instability.
- Ongoing: OTC market listing with associated risks.
Growth Opportunities
- Expanding Product Line: GeneLink can expand its product line to include more specialized DNA assessments and personalized health solutions. The global nutrigenomics market, which includes personalized nutrition based on genetic information, is projected to reach $1.2 billion by 2027. By introducing new products tailored to specific health concerns, GeneLink can attract a broader customer base and increase revenue. Timeline: 12-18 months to develop and launch new products.
- Strategic Partnerships: Forming strategic partnerships with healthcare providers, wellness centers, and fitness companies can expand GeneLink's distribution channels and reach new customers. Collaborating with established players in the health and wellness industry can provide access to a wider audience and enhance credibility. The market for health and wellness partnerships is growing, with companies increasingly seeking to offer integrated solutions to their customers. Timeline: 6-12 months to establish partnerships.
- International Expansion: Expanding into international markets can significantly increase GeneLink's customer base and revenue potential. The global market for personalized medicine is growing rapidly, with significant opportunities in Asia and Europe. By adapting its products and marketing strategies to local markets, GeneLink can tap into new sources of growth. Timeline: 18-24 months to establish international operations.
- Direct-to-Consumer Marketing: Enhancing its direct-to-consumer marketing efforts can increase brand awareness and drive sales. Utilizing digital marketing channels, social media, and influencer marketing can effectively reach target customers and promote GeneLink's products. The market for direct-to-consumer healthcare products is growing, with consumers increasingly seeking convenient and accessible solutions. Timeline: Ongoing, with continuous optimization of marketing strategies.
- Data Analytics and Personalization: Leveraging data analytics to further personalize its products and services can enhance customer satisfaction and loyalty. By analyzing customer data and genetic information, GeneLink can provide more tailored recommendations and solutions. The market for personalized healthcare is driven by the increasing availability of data and advancements in data analytics technologies. Timeline: Ongoing, with continuous improvement of data analytics capabilities.
Opportunities
- Expanding product line to include more specialized DNA assessments.
- Forming strategic partnerships with healthcare providers.
- Expanding into international markets.
- Leveraging data analytics to further personalize products and services.
Threats
- Competition from established players in the biotechnology sector.
- Regulatory changes affecting DNA assessment and supplement industries.
- Economic downturn impacting consumer spending on personalized health solutions.
- Negative publicity or scientific studies questioning the effectiveness of DNA-based personalized health.
Competitive Advantages
- Proprietary DNA assessment technology.
- Customized supplement formulations based on genetic information.
- Personalized skincare product line.
- Focus on individualized health solutions.
About GNLKQ
GeneLink, Inc., established in 1994 and based in Orlando, Florida, operates within the healthcare sector, specifically in biotechnology. The company focuses on personalized health solutions, primarily offering 12-gene DNA assessment services. These assessments are designed to provide insights into an individual's genetic predispositions, which GeneLink then uses to formulate health custom supplements tailored to the individual's needs. In addition to supplements, GeneLink formulates and markets a line of skin care products also designed with personalized health in mind. GeneLink's business model centers around leveraging genetic information to create individualized health and wellness products. The company caters to consumers interested in proactive and personalized healthcare solutions. However, it currently faces challenges related to profitability, as indicated by its negative profit margin of -142.9%.
What They Do
- Offers 12-gene DNA assessment services to provide insights into individual genetic predispositions.
- Formulates health custom supplements based on DNA assessment results.
- Develops and markets a line of skin care products.
- Provides personalized health solutions tailored to individual needs.
- Utilizes genetic information to create individualized health and wellness products.
- Caters to consumers interested in proactive and personalized healthcare solutions.
Business Model
- Generates revenue through the sale of DNA assessment services.
- Generates revenue through the sale of custom supplements formulated based on DNA assessment results.
- Generates revenue through the sale of skin care products.
- Focuses on direct-to-consumer sales through online channels.
Industry Context
GeneLink, Inc. operates in the rapidly evolving biotechnology sector, which is characterized by innovation and personalized medicine. The market for personalized health solutions, including DNA assessment and custom supplements, is growing, driven by increasing consumer awareness and technological advancements. However, the industry is also highly competitive, with numerous companies offering similar services. GeneLink faces competition from established players and emerging startups. The company's success depends on its ability to differentiate its products, effectively market its services, and navigate the complex regulatory landscape of the healthcare industry.
Key Customers
- Individuals interested in personalized health and wellness solutions.
- Consumers seeking proactive healthcare options.
- People looking for customized supplements and skincare products.
- Customers who value genetic insights for health management.
Financials
Chart & Info
GeneLink, Inc. (GNLKQ) stock price: Price data unavailable
Latest News
No recent news available for GNLKQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNLKQ.
Price Targets
Wall Street price target analysis for GNLKQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNLKQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Bernard L. Kasten Jr.
CEO
Bernard L. Kasten Jr. serves as the CEO of GeneLink, Inc. His background includes experience in the healthcare and biotechnology sectors. He has held various leadership positions in companies focused on developing and marketing innovative health solutions. His expertise lies in strategic planning, product development, and market expansion. He is responsible for guiding GeneLink's overall strategy and ensuring the company's growth and profitability.
Track Record: Under Bernard L. Kasten Jr.'s leadership, GeneLink has focused on expanding its product line and enhancing its direct-to-consumer marketing efforts. Key milestones include the development of new DNA assessment services and the launch of personalized skincare products. However, the company continues to face challenges related to profitability and financial stability.
GNLKQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GeneLink may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial disclosure and regulatory oversight.
- Price Volatility: High price fluctuations due to speculative trading and limited market depth.
- Potential for Fraud: Increased risk of fraudulent activities due to less stringent listing requirements.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial instability.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor the company's trading volume and price activity.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with OTC trading.
- Company has been in operation since 1994.
- Offers DNA assessment services, custom supplements, and skincare products.
- Has a CEO in place.
- Operates in the healthcare sector.
GeneLink, Inc. Stock: Key Questions Answered
What does GeneLink, Inc. do?
GeneLink, Inc. specializes in personalized health solutions, offering 12-gene DNA assessment services, custom supplements, and a line of skin care products. The company leverages genetic information to create individualized health and wellness products, catering to consumers interested in proactive and personalized healthcare. GeneLink focuses on direct-to-consumer sales through online channels, providing tailored solutions based on individual genetic predispositions.
What do analysts say about GNLKQ stock?
Currently, there is no available analyst coverage for GNLKQ stock. Given its OTC listing and micro-cap status with a market cap of $0.00B, the stock is unlikely to be actively tracked by major financial analysts. Investors should rely on their own due diligence and research to assess the company's prospects and risks. Key valuation metrics, such as the negative P/E ratio, indicate financial challenges that warrant careful consideration.
What are the main risks for GNLKQ?
The main risks for GNLKQ include its negative profit margin and financial instability, as evidenced by its -142.9% profit margin. The company's OTC market listing introduces additional risks related to liquidity, transparency, and regulatory oversight. Increased competition from established players in the biotechnology sector and potential regulatory changes affecting DNA assessment and supplement industries also pose significant threats. Investors should carefully assess these risks before investing in GNLKQ.
What are the key factors to evaluate for GNLKQ?
GeneLink, Inc. (GNLKQ) currently holds an AI score of 49/100, indicating low score. Key strength: Personalized health solutions based on DNA assessment.. Primary risk to monitor: Potential: Increased competition from established players in the biotechnology sector.. This is not financial advice.
How frequently does GNLKQ data refresh on this page?
GNLKQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNLKQ's recent stock price performance?
Recent price movement in GeneLink, Inc. (GNLKQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Personalized health solutions based on DNA assessment.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNLKQ overvalued or undervalued right now?
Determining whether GeneLink, Inc. (GNLKQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNLKQ?
Before investing in GeneLink, Inc. (GNLKQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and subject to change.